Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Mexico"

70 News Found

Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico
News | August 18, 2025

Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico

The projected business potential is around US$ 1 million in the first year


Lupin and Scope sign agreement for commercialization of Optase in Mexico
News | October 08, 2024

Lupin and Scope sign agreement for commercialization of Optase in Mexico

The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions


Lupin and Huons Sign agreement for commercialization of cyclosporine ophthalmic nanoemulsion in Mexico
News | July 22, 2024

Lupin and Huons Sign agreement for commercialization of cyclosporine ophthalmic nanoemulsion in Mexico

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome


Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Biotech | November 20, 2021

Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam

Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical


Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection
Drug Approval | October 05, 2025

Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

The NDA submission follows the successful completion of a pivotal Phase III global clinical trial


Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections
Drug Approval | October 01, 2025

Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections

This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company


Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC
Clinical Trials | September 06, 2025

Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC

The company has received approval from DCGI to begin patient enrolment and dosing in the country